Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Sosei Group ( (JP:4565) ).
Nxera Pharma has reached a second development milestone in its multi-target collaboration and license agreement with Eli Lilly, focused on discovering treatments for diabetes and metabolic diseases. The milestone, which triggers an undisclosed payment from Lilly, reflects significant progress in Nxera’s research and development activities under the partnership.
The achievement validates the use of Nxera’s NxWave platform to identify small molecule binders to GPCR targets and determine receptor structures in complex with those molecules, clarifying their binding sites. Under the deal, Lilly will now lead further development and commercialization, while Nxera remains eligible for up to US$694 million in future development and commercial milestones, plus tiered royalties on global sales, underscoring the collaboration’s potential long-term financial and strategic value.
The most recent analyst rating on (JP:4565) stock is a Hold with a Yen990.00 price target. To see the full list of analyst forecasts on Sosei Group stock, see the JP:4565 Stock Forecast page.
More about Sosei Group
Nxera Pharma is a technology-powered biopharmaceutical company focused on developing new specialty medicines for patients with unmet medical needs in Japan and globally. It operates a commercial business in Japan and the broader APAC region, advancing an internal and partnered pipeline built on its proprietary NxWave GPCR structure-based drug discovery platform, with operations in Japan, the UK, Switzerland and South Korea and a listing on the Tokyo Stock Exchange.
Average Trading Volume: 868,800
Technical Sentiment Signal: Sell
Current Market Cap: Yen90.77B
For detailed information about 4565 stock, go to TipRanks’ Stock Analysis page.